STOCK TITAN

Xilio Therapeutics (XLO) 10-K Filings

XLO NASDAQ

Here are the 10-K annual reports from Xilio Therapeutics, Inc. (XLO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow XLO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XLO filings page.

Rhea-AI Summary

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on masked immuno-oncology therapies that activate mainly inside tumors to improve cancer outcomes while limiting side effects. The company implemented a 1‑for‑14 reverse stock split of its common stock on March 13, 2026.

Xilio’s pipeline includes XTX501, a bispecific PD‑1/masked IL‑2 antibody fusion protein expected to enter Phase 1 after an IND filing targeted for mid‑2026, and two wholly owned masked T‑cell engager programs directed at PSMA/STEAP1 and CLDN18.2 with planned IND submissions in 2027. Efarindodekin alfa, a masked IL‑12, showed early anti‑tumor activity and tolerability in Phase 1 and is in an ongoing Phase 2 trial.

The company has major collaborations: with Gilead for efarindodekin alfa and other IL‑12 molecules, with up to $575 million in potential milestones plus royalties, and with AbbVie on up to four masked immunotherapy programs, with up to about $2.1 billion in potential contingent payments plus royalties. As of June 30, 2025, non‑affiliate common stock held an aggregate market value of about $34.9 million, and 5,782,511 shares were outstanding as of March 18, 2026.